公开(公告)号：US20240299458A1

公开(公告)日：2024-09-12

申请号：US18575031

申请日：2022-06-30

Applicant: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE ,  JAPANESE RED CROSS SOCIETY

Inventor： Akihiko TAGUCHI ,  Akie TAURA ,  Yuka OKINAKA ,  Yuko OGAWA ,  Takafumi KIMURA ,  Mitsunobu TANAKA ,  Kazuta YASUI ,  Akihiro FUCHIZAKI ,  Teruhito YASUI

IPC: A61K35/28 ,  A61P9/04 ,  A61P9/10 ,  C12N5/0789 ,  C12N13/00

CPC classification number: A61K35/28 ,  A61P9/04 ,  A61P9/10 ,  C12N5/0647 ,  C12N13/00

Abstract: The present invention relates to a pharmaceutical composition comprising a population of cells including irradiated hematopoietic stem cells, and a method for producing the pharmaceutical composition, specifically, a pharmaceutical composition for treating an ischemic disease, comprising a population of cells including irradiated hematopoietic stem cells, wherein the irradiation is irradiation at 50 Gy or less, and a method for producing the pharmaceutical composition.

公开(公告)号：US20220265603A1

公开(公告)日：2022-08-25

申请号：US17623109

申请日：2020-06-24

Applicant: NATIONAL HOSPITAL ORGANIZATION ,  NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER ,  Advanced Innovation Development Co., Ltd. ,  FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE

Inventor： Noriko ASAHARA ,  Takayuki INOUE ,  Masashi TANAKA ,  Masafumi IHARA ,  Satoshi SAITO

IPC: A61K31/353 ,  A61P1/16

Abstract: The present invention aims to provide a novel liver fibrosis inhibiting agent or brown adipocyte activating agent, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis which contains the inhibiting agent or activating agent as an active ingredient. The present invention relates to a liver fibrosis inhibiting agent and a brown adipocyte activating agent, each containing taxifolin as an active ingredient, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis, containing taxifolin as an active ingredient.

公开(公告)号：US20220260580A1

公开(公告)日：2022-08-18

申请号：US17628023

申请日：2019-07-19

Applicant: TOKYO ELECTRON LIMITED ,  SHIMADZU CORPORATION ,  FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE

Inventor： Keisuke HARA ,  Shinichi GOMI ,  Tomohisa NAGATA ,  Kenichi KAGAWA ,  Yasuhiro OSHIMA ,  Takashi SUZUKI ,  Masatoshi TAKAHASHI ,  Takako YAMAMOTO ,  Shin KAWAMATA

IPC: G01N33/68 ,  C12N5/0735

Abstract: The present invention relates to a method for evaluating the state of cell differentiation during the process of inducing differentiation of human induced pluripotent stem cells (iPS cells) into retinal pigment epithelial cells. The present invention further relates to a method for evaluating the state of cell differentiation during the process of inducing differentiation of human embryonic stem cells (ES cells) into retinal pigment epithelial cells.

公开(公告)号：US20210046214A1

公开(公告)日：2021-02-18

申请号：US16966226

申请日：2019-01-31

Applicant: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY ,  KINKI UNIVERSITY ,  FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE

Inventor： Takashi YURUBE ,  Yoshiki TAKEOKA ,  Koichi MORIMOTO ,  Saori KUNII ,  Kaoru OMAE

IPC: A61L27/24 ,  C07K14/78 ,  C12N5/077 ,  A61L27/50 ,  A61L27/52

Abstract: A therapeutic agent for intervertebral disc degeneration that contains LASCol obtained by enzymatically cleaving a terminus of collagen.

公开(公告)号：US20210038642A1

公开(公告)日：2021-02-11

申请号：US16977951

申请日：2019-03-05

Applicant: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE

Inventor： Akihiko TAGUCHI

IPC: A61K35/15 ,  A61K35/18 ,  A61K35/19

Abstract: The present invention provides a cell preparation in which a proportion of leukocyte in a normal form and an undesired component containing at least one selected from the group consisting of erythrocyte, deformed cell, platelet and aggregate (undesired component count/leukocyte count) is not more than a predetermined value. The aforementioned predetermined value is preferably 37.0%. In addition, the cell preparation of the present invention can be utilized for the treatment of ischemic diseases such as cerebral infarction, myocardial infarction, limb ischemia, renal infarction, pulmonary infarction, splenic infarction, the intestinal infarction, Buerger disease, cerebrovascular dementia, diabetic nephropathy microangiopathy, diabetic cardiac failure and the like.

公开(公告)号：US20200172969A1

公开(公告)日：2020-06-04

申请号：US16623382

申请日：2018-06-04

Applicant: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE

Inventor： Shin KAWAMATA ,  Takako YAMAMOTO ,  Chiemi TAKENAKA

IPC: C12Q1/6876 ,  C12Q1/02 ,  C12N5/074

Abstract: The invention provides a method for predicting a differentiation potential of a pluripotent stem cell comprising measuring an expression level of CHD7 of the human pluripotent stem cell. The invention also provides a method for evaluating a medium for a human pluripotent stem cell comprising measuring an expression level of CHD7 of the pluripotent stem cell.

公开(公告)号：US10278926B2

公开(公告)日：2019-05-07

申请号：US15525281

申请日：2015-11-11

Applicant: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE ,  OSAKA MEDICAL COLLEGE ,  Masaaki Ii ,  Yasuhiko Tabata

Inventor： Masaaki Ii ,  Yasuhiko Tabata

IPC: A61K9/51 ,  A61K45/00 ,  A61K47/34 ,  A61K9/16 ,  A61K31/366 ,  A61K35/12 ,  A61K47/69 ,  A61K9/14 ,  A61K35/34 ,  A61K39/00

Abstract: A preparation containing a statin-encapsulated nanoparticle obtained by encapsulating statin in a nanoparticle containing a bioabsorbable polymer is disclosed. The nanoparticle has a number average particle diameter of less than 1000 nm. The preparation is used to enhance the function of a stem cell. A stem cell with an enhanced function is disclosed. The stem cell takes up and contains the statin-encapsulated nanoparticle.

公开(公告)号：US10055665B2

公开(公告)日：2018-08-21

申请号：US15267590

申请日：2016-09-16

Applicant: Foundation for Biomedical Research and Innovation at Kobe ,  Nihon Medi-Physics Co., Ltd.

Inventor： Go Akamatsu ,  Michio Senda ,  Yasuhiko Ikari ,  Shuya Miki

IPC: G06K9/32 ,  A61B6/00 ,  G06K9/46 ,  G06T7/00 ,  G06K9/62 ,  G06T11/00 ,  A61B6/03 ,  A61B5/00 ,  G06T7/33 ,  A61B5/055 ,  G01R33/48

CPC classification number: G06K9/3233 ,  A61B5/0035 ,  A61B5/055 ,  A61B5/4082 ,  A61B5/4088 ,  A61B5/7425 ,  A61B5/7485 ,  A61B6/037 ,  A61B6/461 ,  A61B6/469 ,  A61B6/501 ,  A61B6/5211 ,  A61B2576/026 ,  G01R33/481 ,  G06K9/6255 ,  G06T7/0012 ,  G06T7/337 ,  G06T11/006 ,  G06T11/008 ,  G06T2207/10088 ,  G06T2207/10104 ,  G06T2207/20128 ,  G06T2207/30016

Abstract: In imaging analysis of a living body, a Region Of Interest (ROI) is set on the basis of the state of radiopharmaceutical accumulation. An example for setting an ROI includes: performing first transformation for anatomically standardizing, with the use of a positive template, a nuclear medicine image acquired by applying a radiopharmaceutical to a subject; performing second transformation for anatomically standardizing, with the use of a negative template, the nuclear medicine image; calculating a degree of similarity between a first anatomical standardization image acquired by the first transformation and the positive template; calculating a degree of similarity between a second anatomical standardization image acquired by the second transformation and the negative template; and applying, to an ROI template, inverse transformation of the first transformation or the second transformation, whichever has the higher of the calculated degrees of similarity, in order to set the ROI.